Table 2.
Whole Population (102) | Secondary Endpoint | ||||||
---|---|---|---|---|---|---|---|
Clinical Features | No Death (84) | Death (18) | p | ||||
Age | 66 | ±14 | 64.6 | ±15 | 73.3 | ±9 | <0.01 |
Male gender | 72 | 71% | 60 | 71.4% | 12 | 66.7% | 0.7 |
Diabetes | 14 | 13.7% | 13 | 15.5 | 1 | 5.6% | 0.3 |
CKD | 30 | 29.4% | 22 | 26.2% | 8 | 44.4% | 0.1 |
Embolic events | 39 | 38.2% | 30 | 35.7% | 9 | 50% | 0.3 |
Injective drug addiction | 14 | 13.7% | 13 | 15.5% | 1 | 5.6 | 0.5 |
Atrial fibrillation | 22 | 21.6% | 17 | 20.2% | 5 | 27.8% | 0.5 |
IT | 7 | 6.9% | 6 | 7.1% | 1 | 5.6% | 0.9 |
IE-aHF | 33 | 32.4% | 22 | 26.2% | 11 | 61.1% | <0.01 |
IE on prosthesis | 51 | 50% | 39 | 46.4% | 12 | 66.7% | 0.1 |
Days S-D | 20 | (7–50) | 21 | 7–60 | 7 | 5–20 | 0.07 |
Laboratory data | |||||||
WBCC admission (×103/µL) | 14 | (9–28) | 13.9 | 8.5–18 | 14 | 9–17 | 0.8 |
CRP admission (mg/dL) | 4 | (1.5–9.7) | 3.8 | 1.4–7.6 | 8 | 3.9–16 | 0.02 |
PCT admission (µg/L) | 0.13 | (0–0.78) | 0.1 | 0–0.5 | 0.6 | 0.0–3.6 | 0.3 |
WBCC peak (×103/µL) | 19 | (14–62) | 19 | 15–24 | 19 | 14–25 | 0.5 |
CRP peak (mg/dL) | 10.6 | (4.2–17.5) | 10.6 | 1.8–17 | 13.1 | 3.9–18.9 | 0.7 |
PCT peak (µg/L) | 0.60 | (0.14–3.2) | 0.1 | 0–2 | 2 | 0–8 | 0.01 |
Imaging Features | |||||||
LVEF (%) | 55 | ±11 | 56 | ±9 | 48 | ±16 | <0.05 |
Vegetation | 85 | 83.3% | 71 | 84.5% | 14 | 77.8% | 0.5 |
Abscess | 30 | 29.4% | 21 | 25% | 9 | 50% | 0.03 |
Fistula | 3 | 2.9% | 3 | 3.6% | 0 | 0% | 0.4 |
Leaflet perforation | 26 | 25.5% | 24 | 28.6% | 2 | 11.1% | 0.1 |
Pseudoaneurysm | 10 | 9.8% | 9 | 10.7% | 1 | 5.6% | 0.7 |
Prosthetic detachment | 24 | 23.5% | 15 | 17.9% | 9 | 50% | <0.01 |
CKD: chronic kidney disease; IT: immunosuppressive treatment; IE: infective endocarditis; IE-aHF: infective endocarditis-related heart failure; S-D: symptoms to diagnosis; WBCC: white blood cell count; CRP: C-reactive protein; PCT: procalcitonin; LVEF: left ventricular ejection fraction.